A Phase I Study of CDK4/6 Inhibitor LEE011 Combined With Gemcitabine in Patients With Advanced Solid Tumors or Lymphoma

Trial Profile

A Phase I Study of CDK4/6 Inhibitor LEE011 Combined With Gemcitabine in Patients With Advanced Solid Tumors or Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Ribociclib (Primary) ; Gemcitabine
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Sep 2016 Status changed from active, no longer recruiting to discontinued as PI left institute.
    • 14 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 06 Aug 2015 Patient inclusion and exclusion criteria been amended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top